HLS Therapeutics Inc (id:13657 HLS)
3.42 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 9:00:08 AM)
Exchange closed, opens in 2 days
About HLS Therapeutics Inc
Market Capitalization 100.47M
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
| Headquarters (address) |
10 Carlson Court Etobicoke M9W 6L2 ON Canada |
| Phone | 647 495 9000 |
| Website | https://www.hlstherapeutics.com |
| Employees | 91 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | HLS |
| Exchange | Toronto Stock Exchange |
| Currency | CAD |
| 52 week range | 3.00 - 5.48 |
| Market Capitalization | 100.47M |
| Dividend yield forward | 6.04 % |
| Dividend yield forward Canada (ID:82, base:385) | 5.73 % |
| P/E trailing | -3.89 |
| P/E forward | -6.32 |
| Price/Sale | 1.76 |
| Price/Book | 1.27 |
| Beta | 1.07 |
| EPS | -0.970 |
| EPS Canada (ID:82, base:722) | 1.84 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: HLS Therapeutics Inc has raised their dividend 6.04 years in a row. This is below the 41189.377500 year average in the 'Drug Manufacturers Specialty & Generic' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: HLS Therapeutics Inc has raised their dividend 6.04 years in a row. This is below the 41189.377500 year average in the 'Drug Manufacturers Specialty & Generic' industry